Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer
NCT ID: NCT00067015
Last Updated: 2015-12-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
3 participants
INTERVENTIONAL
2003-05-31
2008-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: Randomized phase III trial to compare the effectiveness of high-dose radiation therapy with or without bicalutamide and goserelin in treating patients who have prostate cancer.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Compare the quality of life of patients with high-grade intermediate-risk or unfavorable-risk adenocarcinoma of the prostate when treated with high-dose intensity-modulated radiotherapy alone versus with androgen deprivation comprising bicalutamide and goserelin.
* Compare the prostate-specific antigen relapse-free, distant metastases-free, and overall survival of patients treated with these regimens.
* Compare the toxicity of these regimens in these patients.
* Compare the local control in patients treated with these regimens, based on post-treatment sextant biopsies performed 4 years after study completion.
OUTLINE: This is a randomized study. Patients are stratified according to prostate-specific antigen level, Gleason score, and clinical stage. Patients are randomized to 1 of 2 treatment arms.
* Arm I: Patients undergo high-dose intensity-modulated radiotherapy (IMRT) 4-5 times per week for 10 weeks (a total of 48 treatments).
* Arm II: Patients receive oral bicalutamide once daily for 18.5 weeks. Three to seven days after the initiation of bicalutamide, patients also receive goserelin subcutaneously monthly for 2 years. Beginning after 10 weeks of hormonal therapy, patients undergo concurrent high-dose IMRT 4-5 times per week for 8.5 weeks (a total of 42 treatments). Patients discontinue bicalutamide on or near the end of radiotherapy.
In both arms, treatment continues in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed at baseline, every 3 months for 1.5 years after the completion of radiotherapy, then 6 months later, and then annually for 2 years.
Patients are followed every 6-8 months for 4 years and then annually for 2 years.
PROJECTED ACCRUAL: A total of 400 patients (200 per treatment arm) will be accrued for this study within 4-5 years.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
IMRT alone to 86.4 Gy
External radiotherapy is given for 10 weeks, Monday through Friday for a total of 48 sessions. The total dose of radiotherapy delivered during these 10 weeks is 86.4 Gy. The radiation treatments are delivered with a high precision technique called intensity modulated radiotherapy or IMRT. For this treatment, no hormonal therapy is required.
assessment of therapy complications
quality-of-life assessment
radiation therapy
IMRT TO 75.6 Gy plus Adjuvant Androgen Deprivation
Prior to a planned course of radiotherapy, which will last for eight and a half weeks, 10 weeks of hormonal therapy are given. The hormonal therapy will start with a daily pill called Casodex. Three to seven days after starting this pill, a Zoladex injection will be administered in addition to the Casodex pill. Zoladex hormonal therapy is given in the form of a monthly injection. After 10 weeks from the initiation of hormone therapy, you will begin external radiotherapy. For these treatments only 42 treatment sessions are given. The total dose of radiotherapy delivered during these 8.5 weeks is 75.6 Gy. The hormone injections continue during the radiation treatments and for 2 years after the radiation treatments. The pills are only taken for the 10 weeks before and also during the radiation treatments, however afterwards the pills are discontinued.
bicalutamide
goserelin acetate
assessment of therapy complications
quality-of-life assessment
radiation therapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
bicalutamide
goserelin acetate
assessment of therapy complications
quality-of-life assessment
radiation therapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically confirmed adenocarcinoma of the prostate
* Unfavorable-risk disease, including at least 2 of the following characteristics:
* Prostate-specific antigen level greater than 10 ng/mL
* Gleason score greater than 7
* Stage T4
* Intermediate-risk disease with a Gleason score of at least 8 allowed
* Lymph nodes clinically negative by imaging studies or histologically negative by node sampling or lymph node dissection
* Prostate size less than 75 grams
* No distant metastases by bone scan, CT scan, or MRI
PATIENT CHARACTERISTICS:
Age
* 18 and over
Performance status
* Karnofsky 80-100%
Life expectancy
* Not specified
Hematopoietic
* Not specified
Hepatic
* Bilirubin no greater than 1.5 times upper limit of normal (ULN)
* SGOT and SGPT no greater than 1.5 times ULN
Renal
* Not specified
Other
* No documented history of inflammatory bowel disease
* No bilateral hip replacements
* No other invasive cancer except localized basal cell or squamous cell skin cancer unless disease free for at least 5 years
* No major medical or psychiatric illness that would preclude study completion, compliance, or follow-up
PRIOR CONCURRENT THERAPY:
Biologic therapy
* Not specified
Chemotherapy
* No prior chemotherapy for prostate cancer
Endocrine therapy
* No prior androgen-deprivation therapy
Radiotherapy
* No prior pelvic radiotherapy
* No prior prostate brachytherapy
Surgery
* No prior bilateral orchiectomy
* No prior radical prostatectomy
* No prior cryotherapy for prostate cancer
18 Years
120 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Memorial Sloan Kettering Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael J. Zelefsky, MD
Role: PRINCIPAL_INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MSKCC-03040
Identifier Type: -
Identifier Source: secondary_id
03-040
Identifier Type: -
Identifier Source: org_study_id